A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506576-27-00

Acronym

73841937NSC3003

Enrollment

170

Registered

2024-06-12

Start date

2020-09-30

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

Brief summary

PFS according to RECIST v1.1 by blinded independent central review

Interventions

DRUGTAGRISSO 40 mg film-coated tablets

DRUGTAGRISSO 80 mg film-coated tablets

DRUGJNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

DRUGplacebo capsule G065

DRUGJNJ-73841937

DRUGplacebo capsule G040

DRUGJNJ-61186372

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS according to RECIST v1.1 by blinded independent central review	—

Countries

Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026